

September 25, 2018



BioCorRx CEO Brady Granier Discusses BioCorRx Recovery Program on This Life #YouLive Podcast Hosted by Dr. Drew

ANAHEIM, CA, Sept. 25, 2018 (GLOBE NEWSWIRE) -- via **NEWMEDIAWIRE**-- **BioCorRx Inc. (OTCQB: BICX) (the "Company")**, a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, appeared as a guest on This Life #YouLive podcast with Dr. Drew, a board-certified internist, addiction medicine specialist, and media personality. Dr. Drew Pinsky explores all aspects on This Life #YouLive with co-hosts Bob Forrest (Celebrity Rehab) and longtime broadcasting partner, Mike Catherwood. Topics include addiction, politics, social issues, current news and everything in between.

Brady Granier joins Bob Forrest and Drew to talk about BioCorRx®, and its recovery program focused on improving the lives of those struggling with alcohol and opioid addiction. The centerpiece of the BioCorRx Recovery program is a proprietary long-lasting implant of Naltrexone.

The podcast can be listened to online at <http://drdrew.com/2018/youlive-151-brady-granier/>.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
investors@BioCorRx.com
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com



Source: BioCorRx Inc